Items where authors include "Kosloski, M.P."

Article

Kosloski, M.P. orcid.org/0000-0002-6642-2439, Guttman‐Yassky, E. orcid.org/0000-0002-9363-324X, Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (13 more authors) (2024) Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials. Clinical and Translational Science, 17 (8). e13874. ISSN 1752-8054

Cork, M.J., Thaçi, D., Eichenfield, L.F. et al. (8 more authors) (2023) Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis. Dermatology and Therapy, 13. pp. 2697-2719. ISSN 2193-8210

Blauvelt, A., Guttman-Yassky, E., Paller, A.S. et al. (13 more authors) (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 23 (3). pp. 365-383. ISSN 1175-0561

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (12 more authors) (2021) Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology, 184 (5). pp. 857-870. ISSN 0007-0963

Paller, A.S., Siegfried, E.C., Simpson, E.L. et al. (12 more authors) (2021) A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35 (2). pp. 464-475. ISSN 0926-9959